Skip to main
  1. Stocks
  2. BridgeBio Pharma Inc
  3. Forecast
BBIO

BBIO Stock Forecast & Price Target

BBIO Analyst Ratings

Based on 18 analyst ratings
Buy
Strong Buy 33%
Buy 61%
Hold 6%
Sell 0%
Strong Sell 0%

Bulls say

BridgeBio Pharma is supported by Attruby’s strong commercial execution, with Q3 US sales of $253MM beating consensus by 2% and growing 14% sequentially and 134% year over year, while de-stocking was minimal and frontline share continued to expand. Its positive outlook is further reinforced by a late-stage pipeline with multiple near-term catalysts: BBP-418, encaleret, and infigratinib all posted compelling Phase III data, have clear regulatory paths, and target large orphan markets with blockbuster potential. BridgeBio also ended Q3 with $1.5B in cash and expects operating losses to narrow from $350-375MM in 2026 to about $250MM in 2027, supporting commercialization momentum and a path to profitability in early-2028.

Bears say

BridgeBio Pharma is exposed to severe balance-sheet risk because it carries about $1.9B in debt and only limited cash reserves, leaving little cushion if late-stage programs underperform. Its outlook is further pressured by the possibility that Attruby cannot meaningfully penetrate the ATTR-CM market amid competitive pressure and weak clinical adoption, while infigratinib faces adoption risk in the US market and other pipeline assets may fail to show adequate safety and efficacy. If these commercialization and development risks materialize, the company may struggle to service lenders or sustain operations, raising bankruptcy risk.

BBIO has been analyzed by 18 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 61% recommend Buy, 6% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of BridgeBio Pharma Inc and is not a guaranteed prediction by Public.com or investment advice.

BBIO Analyst Forecast & Price Prediction

Get the latest BBIO stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in BBIO

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About BridgeBio Pharma Inc (BBIO) Forecast

Analysts have given BBIO a Buy based on their latest research and market trends.

According to 18 analysts, BBIO has a Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $105.72, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $105.72, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

BridgeBio Pharma Inc (BBIO)


BBIO Analyst Forecast & Price Prediction

Get the latest BBIO stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in BBIO

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover BBIO stock data and trends